Affordable Access

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.

Authors
Type
Published Article
Journal
World Journal of Gastroenterology
1007-9327
Publisher
Baishideng Publishing Group Co
Publication Date
Volume
13
Issue
33
Pages
4458–4466
Identifiers
PMID: 17724801
Source
Medline
License
Unknown

Abstract

The growth of human cholangiocarcinoma cells can be potently inhibited by MS-275 alone or in combination with conventional cytostatic drugs or new, targeted anticancer agents.

Statistics

Seen <100 times